Last Updated: June 23, 2026

ALCAFTADINE Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Alcaftadine, and when can generic versions of Alcaftadine launch?

Alcaftadine is a drug marketed by Alembic, Eugia Pharma, and Gland. and is included in three NDAs.

The generic ingredient in ALCAFTADINE is alcaftadine. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the alcaftadine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Alcaftadine

A generic version of ALCAFTADINE was approved as alcaftadine by GLAND on March 1^st, 2024.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ALCAFTADINE?
What are the global sales for ALCAFTADINE?
What is Average Wholesale Price for ALCAFTADINE?

Summary for ALCAFTADINE

US Patents:	0
Applicants:	3
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ALCAFTADINE

Paragraph IV (Patent) Challenges for ALCAFTADINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LASTACAFT	Ophthalmic Solution	alcaftadine	0.25%	022134	1	2014-07-30

US Patents and Regulatory Information for ALCAFTADINE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	ALCAFTADINE	alcaftadine	SOLUTION/DROPS;OPHTHALMIC	209290-001	Oct 2, 2024		OTC	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Eugia Pharma	ALCAFTADINE	alcaftadine	SOLUTION/DROPS;OPHTHALMIC	210659-001	Jun 23, 2023		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Gland	ALCAFTADINE	alcaftadine	SOLUTION/DROPS;OPHTHALMIC	209706-001	Mar 1, 2024		OTC	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.